Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selonsertib in NASH with bridging (F3) fibrosis
2016-004374-18Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Selonsertib with Placebo (2 arms). Primary endpoint: Primary Efficacy Endpoint. Started May 2017; status: terminated.
02
Drugs
selonsertib
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2016-004374-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004374-18.